'Unprecedented' Responses to Neoadjuvant Treatment in dMMR Colon Cancer
12/09 - "Unprecedented" pathologic responses were seen after a neoadjuvant 4-week course of ipilimumab (Yervoy) plus nivolumab (Opdivo) was given before surgery to patients with DNA mismatch repair deficient (dMMR) colon cancer, say researchers reporting new results from the NICHE-2 trial.
he trial involved 112 patients with dMMR colon cancer who were given one cycle of low-dose ipilimumab and two cycles of nivolumab followed by surgery.
The results show that 95% of patients had a major pathologic response (MPR) and 67% had a pathologic complete response (pCR) to immunotherapy.
To date, none of these patients have had disease recurrence after a median follow-up of 13.1 months.
Wilt u de rest van dit artikel lezen?
Registreer gratis om toegang te krijgen tot de volledige inhoud van MediQuality op al uw schermen